Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
---|
12/27/2006 | CN1886148A Selective inhibition of NF-kB activation by peptides designed to disrupt NEMO oligomerization |
12/27/2006 | CN1886131A Composition and method for treating macular degeneration |
12/27/2006 | CN1886128A Compositions and methods for treating burns |
12/27/2006 | CN1884554A Eucaryotic expression vector for treating tumour transfer and its construct method |
12/27/2006 | CN1884550A Novel subtype CaMKII alpha3 gene and clone method, expressed protein and uses |
12/27/2006 | CN1884521A Method for finding novel gene and computer system platform using same and novel gene |
12/27/2006 | CN1884503A Bamboo leaf SOD preparation and functionalized food containing bamboo leaf SOD |
12/27/2006 | CN1883709A Bi-functional targeting antineoplastic polypeptide and application thereof |
12/27/2006 | CN1883703A Serine protease inhibitor of Rana grahami, its gene and application |
12/27/2006 | CN1883702A Medicine for treating deep erosive trauma with crust |
12/27/2006 | CN1883701A Ciliary nerves nutrilite composition having long-time stability |
12/27/2006 | CN1883700A Novel use of xCT protein and its encoding gene |
12/27/2006 | CN1883536A Orally administered cervus and cucumis polypeptide composition and preparation method thereof |
12/27/2006 | CN1883508A Anti-dust nasal cleanser |
12/27/2006 | CN1883457A Lyophilized suspended powder injection and preparation method thereof |
12/27/2006 | CN1292002C Arginine deacylase fusion protein, method for preparation and application |
12/27/2006 | CN1292001C Nucleus factor-kB p50 subunit antagonist peptide, preparation and application thereof |
12/27/2006 | CN1292000C Nucleus factor-kB p65 subunit combination peptide, preparation and application thereof |
12/27/2006 | CN1291998C Ligand of NKG2D acceptor and use |
12/27/2006 | CN1291757C Remedy for inflammatory bowel diseases |
12/27/2006 | CN1291756C Blood cell production via activation of hemeglobin scavenger receptor |
12/27/2006 | CN1291754C Localized anesthesia synergistic delay agent |
12/27/2006 | CN1291718C Remedy for acute myocardial infarction |
12/26/2006 | US7153955 Apparatus for use as diagnostic and therapeutic tool in gene therapy |
12/26/2006 | US7153951 A biologically active peptide at least 85% identical to a peptide: (a) X01ValSerGluX02GlnLeuX03HisX04X05GlyLysX06; (b) fragments containing amino acids 1-9, 1-10, 1-11, 1-12,(c) a salt or (d) N- or C- derivatives |
12/26/2006 | US7153950 For diagnosis of/drugs for inflammatory bowel disease/asthma/ diabetes/arthritis/cirrhosis/skin disorders |
12/26/2006 | US7153949 Nucleic acid encoding poly-zinc finger proteins with improved linkers |
12/26/2006 | US7153947 Ixodes salivary anticomplement protein |
12/26/2006 | US7153946 Molecular conjugates for use in treatment of cancer |
12/26/2006 | US7153944 High affinity integrin polypeptides and uses thereof |
12/26/2006 | US7153943 Derivatives of growth hormone and related proteins, and methods of use thereof |
12/26/2006 | US7153942 Polypeptide for use in the treatment of inflammation, rheumatoid arritis, psoriasis, and diabetic retinopathy |
12/26/2006 | US7153940 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
12/26/2006 | US7153938 Cross-linked apatite/collagen porous body containing self-organized apatite/collagen composite and its production method |
12/26/2006 | US7153936 A peptide of at least 5 amino acids containing a unique portion of a semaphorin, and such peptide has a semaphorin binding specificity |
12/26/2006 | US7153935 Tumor suppressor gene |
12/26/2006 | US7153933 Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
12/26/2006 | US7153932 Immunotoxins comprising ribosome-inactivating proteins |
12/26/2006 | US7153930 Peptide transport |
12/26/2006 | US7153847 Dipeptide-substituted benzo- and dibenzocaprolactams, which inhibit beta -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease |
12/26/2006 | US7153841 Conjugates with carriers; red shifted absorption; antiproliferative and antitumor agents; benign prostatic hyperplasia; diagnosis |
12/26/2006 | US7153836 Having 1-4 hydrophobic C 10-24 aliphatic, saturated or unsaturated hydrocarbon residue moieties covalently bound to a protein with a hedgehog N-terminal domain; includes auxiliary substances, detergents, stabilizers, matrix materials, suramin, heparin, anionic polysaccharides and/or sequestering agents |
12/26/2006 | US7153835 Dipeptides and tripeptides for treating inflammatory reactions, including allergic reactions |
12/26/2006 | US7153834 A homogeneous cyclosporin solution comprising a carrier dialkyl ester of aliphatic or aromatic dioic acid, hydrophilic lipophilic balance, forming emulsions in stomach with gastrointestinal fluids |
12/26/2006 | US7153833 Therapeutic uses of SMR1 peptides |
12/26/2006 | US7153832 Compositions of active Wnt protein |
12/26/2006 | US7153831 Rabconnectin-3-binding protein |
12/26/2006 | US7153830 Administering factor XIII systemically optionally in conjunction with activated thrombin. |
12/26/2006 | US7153829 Preventing or reducing neurocognitive defects due to reperfusion injury and/or damage to the central nervous system, such as cerebral ischemia caused by various kinds of strokes, by administering a polypeptide inhibitor of plasma kallikrein, Ecallantide |
12/26/2006 | US7153828 Use of heregulin as a growth factor |
12/26/2006 | US7153827 Produced by recombinant techniques; stimulating angiogenesis for wound healing and for vascular tissue repair |
12/26/2006 | US7153826 Cyclic peptide antibiotics including the loloatins are effective in the treatment of rosacea, particularly when administered in conjunction with an antibiotic such as metronidazole that is effective against anaerobic bacteria. |
12/26/2006 | US7153825 Administering an exendin modified with a polyethylene glycol, gelatin and/or albumin to increase its biological half-life; treating hyperglucagonemia and diabetes, especially type II diabetes |
12/26/2006 | US7153824 Inhibitors of phosphodiesterases in infertility |
12/26/2006 | US7153823 Methods of use of fibroblast growth factor, vascular endothelial growth factor and related proteins in the treatment of acute and chronic heart disease |
12/26/2006 | US7153822 Compositions and methods for modulating connexin hemichannels |
12/26/2006 | US7153683 Present invention relates generally to compositions and methods for modulating activity of MAP/ERK kinase MEK3 and/or other MEK family members; is particularly related to polypeptide variants of TAO proteins |
12/26/2006 | US7153678 Polynucleotides encoding the novel human phosphatase, RET31, and variants thereof |
12/26/2006 | US7153669 Nucleotide sequences coding protein for use in the diagnosis, treatment and prevention of autoimmune, cell proliferative and inflammatory diseases |
12/26/2006 | US7153668 Nucleotide sequences coding polypeptide for use in the treatment of cardiovascular disoders |
12/26/2006 | US7153664 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory disorders |
12/26/2006 | US7153662 Inflammation-specific peptides and the uses thereof |
12/26/2006 | US7153661 Artificial antibody polypeptides |
12/26/2006 | US7153659 Bioassay for measuring the proliferation of T-cells in Human papiloma virus |
12/26/2006 | US7153657 Detecting cell proliferation disorders of lung, liver and/or pancreas which are associated with tumor suppressor lung cancer 1 polypeptide (TSLC1) |
12/26/2006 | US7153529 Administering hemagglutinins |
12/26/2006 | US7153522 bases comprising isoprene-styrene block copolymer and/or polyisobutylene, softeners and tackifier resins, hexylene glycol and 1-menthol as skin absorption intensifiers, and hormones as the drug components |
12/26/2006 | US7153519 Implantable substrate coated with a macromer having free radical polymerizable substituents |
12/26/2006 | US7153515 Method of preventing T cell-mediated responses by the use of the major histocompatibility complex class II analog protein (map protein) from Staphylococcus aureus |
12/26/2006 | US7153514 Use of botulinum toxin therapy for prostatic hyperplasia and related disorders |
12/26/2006 | US7153508 Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
12/26/2006 | US7153505 Degrading extracellular collogen or elastin of obstructing tissue by administering a collagenase, elastase or trypsin inhibitor to dissolve and remove; softening the remaining tissue, balloon dilation at lower pressures in less mechanical trauma; deblocking artery, vein, ureteter, bronchi, bile duct |
12/26/2006 | US7153504 animal feed additives comprising blends of biological organs, soy hulls and proenzymes, having stability in air and water |
12/26/2006 | US7153503 Comprehensive dietary supplement |
12/26/2006 | US7153499 Promoting differentiation and maturation of immature dendritic cells in a regional lymph node (especially by administering a natural cytokine mixture parilymphatically) so that the cells deliver T-cell antigen to effect immunization |
12/21/2006 | WO2006135846A2 Methods and systems for neural maintenance and regeneration |
12/21/2006 | WO2006135811A2 Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells |
12/21/2006 | WO2006135783A2 Compositions and methods for modulating angiogenesis |
12/21/2006 | WO2006135762A1 Identification of a folliculin-binding protein fnip1 |
12/21/2006 | WO2006135740A1 Pegylated hemoglobin and albumin and uses thereof |
12/21/2006 | WO2006135739A2 A novel conotoxin framework with a helix-loop-helix fold |
12/21/2006 | WO2006135733A2 Modulation of peripheral clocks in adipose tissue |
12/21/2006 | WO2006135660A2 Therapies involving lymphotoxin beta receptor |
12/21/2006 | WO2006135506A2 Compositions for topical enzymatic debridement |
12/21/2006 | WO2006135493A2 A composition for wound healing and use thereof |
12/21/2006 | WO2006135385A2 Antagonizing interleukin-21 receptor activity |
12/21/2006 | WO2006135345A1 Phospholipase(s) and use(s) thereof |
12/21/2006 | WO2006135176A1 Human granulocyte-colony stimulating factor isoforms |
12/21/2006 | WO2006135109A1 Method for treatment of proliferative disease utilizing inhibition of formation of synoviolin homooligomer |
12/21/2006 | WO2006135027A1 Agent for treatment of wound and/or promotion of wound healing |
12/21/2006 | WO2006134692A1 Angiogenetic agent containing adrenomedulin as the active ingredient |
12/21/2006 | WO2006134601A2 Methods for the treatment of renal failure |
12/21/2006 | WO2006134340A2 Oxyntomodulin analogues and their effects on feeding behaviour |
12/21/2006 | WO2006134280A2 Mutated nucleotide sequences of the hepatitis c virus |
12/21/2006 | WO2006133955A1 Adamts13-comprising compositions having thrombolytic activity |
12/21/2006 | WO2006133931A2 Identification of jak/stat pathway modulating genes by genome wide rnai screening |
12/21/2006 | WO2006133853A1 Heterodimeric peptide compounds displaying ngf activity and their use to treat neurodegenerative disorders |
12/21/2006 | WO2006133691A1 Method for determining and influencing the fertility of male mammals and of a human being |
12/21/2006 | WO2006133566A1 NOVEL Aß-BINDING PROTEIN AND ITS PEPTIDE DERIVATIVES AND USES THEREOF |
12/21/2006 | WO2006133553A1 Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |